Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
20 February 2025 - 11:00PM
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the
“Company”), a pharmaceutical company advancing medicines to bring
meaningful improvement to patients' lives through innovative
science and delivery technologies, today announced that it will
report results for the fourth quarter ended December 31, 2024 and
provide an update on recent developments in its business after
market close on Wednesday, March 5, 2025.
Management will host a conference call for
investors at 8:00 a.m. ET on Thursday, March 6, 2025. In order to
participate, please register in advance here to obtain a local or
toll-free phone number and your personal pin.
A live webcast of the call will be available on
the Investors section of Aquestive’s website at: Fourth Quarter
2024 Earnings Call.
Following the call, a replay of the webcast will
be available on the Investors section of the Company’s website at
https://investors.aquestive.com/events-and-presentations. The
webcast will be archived for 30 days.
About Aquestive
TherapeuticsAquestive is a pharmaceutical company
advancing medicines to bring meaningful improvement to patients'
lives through innovative science and delivery technologies. We are
developing orally administered products to deliver complex
molecules, providing novel alternatives to invasive and
inconvenient standard of care therapies. Aquestive has five
commercialized products marketed by the Company and its licensees
in the U.S. and around the world, and is the exclusive manufacturer
of these licensed products. The Company also collaborates with
pharmaceutical companies to bring new molecules to market using
proprietary, best-in-class technologies, like PharmFilm®, and has
proven drug development and commercialization capabilities.
Aquestive is advancing a late-stage proprietary product candidate
for the treatment of severe allergic reactions, including
anaphylaxis, and an earlier stage epinephrine prodrug topical gel
product candidate for the treatment of possible various dermatology
conditions, including alopecia areata. For more information,
visit Aquestive.com and follow us on LinkedIn.
Forward-Looking
StatementCertain statements in this press release include
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,”
“will,” or the negative of those terms, and similar expressions,
are intended to identify forward-looking statements. These
forward-looking statements include, but are not limited to,
statements regarding the advancement for clinical development and
approval by the U.S. Food and Drug Administration of the Company’s
product candidates, including AQST-109 for the treatment of severe
allergic reactions, including anaphylaxis, and AQST-108 for the
treatment of possible various dermatology conditions, including
alopecia areata. These forward-looking statements are based on the
Company’s current expectations and beliefs and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, risks associated with the Company’s development work,
including any delays or changes to the timing, cost and success of
its product development activities and clinical trials and other
risks and uncertainties affecting the Company described in the
“Risk Factors” section and in other sections included in its Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K filed with the U.S. Securities and Exchange
Commission. Given those uncertainties, you should not place undue
reliance on these forward-looking statements, which speak only as
of the date made. All subsequent forward-looking statements
attributable to the Company or any person acting on its behalf are
expressly qualified in their entirety by this cautionary statement.
The Company assumes no obligation to update forward-looking
statements or outlook or guidance after the date of this press
release whether as a result of new information, future events or
otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are
registered trademarks of Aquestive Therapeutics, Inc.
Investor InquiriesAstr
partnersBrian KorbBrian.korb@astrpartners.com
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Jan 2025 to Feb 2025
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Feb 2024 to Feb 2025